NY-DOUXMATOK
14.9.2021 15:02:06 CEST | Business Wire | Press release
Today, DouxMatok (Israel/USA) and Hi-Food (Italy), two food-tech pioneers leading the development of innovative ingredients, announce a partnership to deliver a complete end-to-end nutritional solution for food manufacturers. DouxMatok’s first-of-its-kind sugar-based sugar reduction solution, Incredo® Sugar , alongside Hi-Food’s semi-solid fiber of natural origin, Meltec® , will allow food brands to address sugar reduction in food products without compromising on taste, texture, sweetness or nutrition.
Incredo Sugar, which officially launched last year and is now commercially available in the U.S., enables up to 50% sugar reduction in food products. The ingredient allows room for nutritional ingredients such as fibers and plant-based proteins, creating a natural fit for a joint effort with Hi-Food’s Meltec, an innovative semi-solid ingredient similar to syrup that is based on vegetable fibers of natural origin. In addition to enriched fiber content, Meltec improves structural properties in food products, is neutral in taste and does not alter odors or colors.
“In partnership with Hi-Food, we’ll be able to deliver more than just a specialty ingredient for great tasting sugar reduction solutions to food brands,” said DouxMatok’s Chief Technology Officer, David Tsivion. “We can provide a full nutritional platform that delivers the scalability and functionality needed for food developers and food production, and the sweetness and mouthfeel that consumers have come to expect.”
The collaborative effort between DouxMatok and Hi-Food addresses one of the most common challenges of existing solutions on the market — maintaining sweetness and other sugar functionalities while avoiding the aftertastes often associated with sugar substitute bulking solutions and addressing other missing sugar functionalities. Research and application development teams at both companies have been working together for over a year to test Incredo® Sugar and Meltec® in combination as pillars to full nutritional solutions in various applications.
“We’re really impressed with the collaborative work of our team and our partners at DouxMatok, and we’re confident in the ability of these combined ingredients to provide a solution that the market is lacking,” said Emanuele Pizzigalli, R&D Officer and co-founder at Hi-Food. “Sugar reduction is a key priority for food manufacturers across the globe, and we’re committed to helping them address this challenge through the use of our fibers with Incredo Sugar.”
The companies have developed product prototypes across a range of applications, including cakes, cookies, chocolate, candy, protein bars, energy bars, snacks, and more. The unique combination of these ingredients also provides an added sustainability value for the food industry as a whole, helping to reduce the environmental impact of overconsumption of sugar, and at the same time exploiting the use of high-quality raw materials from well controlled legumes and cereals supply chains. Products utilizing DouxMatok and Hi-Food’s full nutritional solution are expected to launch in early 2022.
To learn more about DouxMatok and Incredo® Sugar, please visit douxmatok.com or incredosugar.com , or follow along on LinkedIn . For more information about Hi-Food and Meltec® , please visit hifood.it , or follow along on LinkedIn . Organizations interested in working with DouxMatok and Hi-Foods can reach out to partnerships@douxmatok.com and info@hifood.it to learn more about product development opportunities.
About Incredo® Sugar
Recognized as a special mention in the ‘Best Inventions of 2020’ by TIME, Incredo® Sugar is the flagship product of DouxMatok , a global food-tech company pioneering the development of efficient nutrition and flavor technologies and enabling tastier and healthier consumption of foods. Incredo® Sugar is a first-of-its-kind, sugar-based sugar reduction solution that improves the efficiency of sugar delivery to the sweet taste receptors and enhances the perception of sweetness enabling substantial sugar reduction without compromising taste, mouthfeel, or texture. Based on real cane sugar, this breakthrough, patented sugar reduction solution enables food manufacturers to develop delicious, better-for-you formulations that deliver great taste experiences and enhance nutritional values of sweet food products while reducing sugar. In April 2021, DouxMatok launched its first product, limited edition Incredo Spreads in two flavors via shop.incredosugar.com . For more information, please visit incredosugar.com , or follow along on Facebook and Instagram .
About DouxMatok
DouxMatok is pioneering the development of efficient nutrition and flavor delivery technologies of food products. Patented through 24 granted patents, its sugar reduction solution, Incredo® Sugar, maximizes the efficiency of sugar delivery to the sweet taste receptors and enhances the perception of sweetness, enabling substantial sugar reduction without compromising taste, mouthfeel, or texture. Independent consumer and expert sensory panel tests have confirmed that, when using Incredo® Sugar, it is possible to reduce 30%-50% of the sugar levels in a wide range of food and snack products while retaining consumer preferences. For more information, please visit douxmatok.com , or follow along on LinkedIn .
About Meltec®
Meltec® – award winning and patented – semi-solid innovative ingredient is rich in fiber and guarantees excellent texturing and bulking properties without sweetening. Produced in Italy, this ingredient made by ingredients of natural origin (corn and chickpeas) is neutral in taste and smell and has less than 1% of sugars. Apparently similar to honey or glucose syrup, Meltec® is suitable for all sugar-free / low-sugar applications, acts as a humectant, texturizing, thickening, filling, cryoprotectant agent and reducing freezing point in a wide range of foods: typical applications include bars, granolas, cakes, ice-creams, sauces and fillings. For more information, please visit hifood.it .
About Hi-Food
Hi-Food was founded in 2012 in Parma, at the heart of Italy’s “Food Valley,” by a group of entrepreneurs with a proven track record in the natural ingredients sector. Over the years, the Company has developed deep expertise and applications knowledge in producing and using natural products, such as new fibers, proteins, gluten-free nucleus, clean label and plant-based systems to create customized functional solutions for conventional and disruptive food industry (traditional bakery, gluten free, gastronomy, sauces, fillings, dessert, ice cream, beverage, new plant-based foods). The R&D team are on-hand to answer questions and solve issues about shelf-life, stability, sugar/salt/fat reduction, egg replacement, fiber/protein enrichment, structure improvement or many other needs which are suitable for its ingredients, and customer finished product. Hi-Food operates research and production facilities in Italy and is expanding its footprint with a state-of-the-art new production plant and R&D application center in Parma. For more information, please visit hifood.it or follow along on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210914005022/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom